View from the Thoraxcenter: AHA 23 Late-break...

In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE throm ...  Show more

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricu ...  Show more

An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.

This podcast is intended for healthcare professionals only. ...

Dr. Zach Cost and Dr. Tem Bendapudi join the show to discuss the literature pertaining to tranexamic acid and thromboembolic risk. Dr. Zach Cost is an anesthesia resident at the Massachusetts General Hospital. Dr. Pavan ("Tem") Bendapudi holds a joint faculty appointment in the D ...  Show more

Sweeten your day with  a review of the updated 2021 USPSTF Prediabetes and Type 2 Diabetes screening guidelines with expert guest Dr. Chien-Wen Tseng! We review the new screening recommendations, assess different testing modalities, talk through screening intervals, and emphasize ...  Show more

<span class="s1"> View the Show Notes Page for This Episode</span>

<span class="s1">